INAHTA Brief

Issue 2011/119

Title **Hybrid Cochlear Implant**

Agency MaHTAS, Health Technology Assessment Section, Medical Development Division, Ministry of Health, Malaysia
Level 4, Block E1, Parcel E, Precinct 1,
Federal Government Administrative Center, 62590 Putrajaya, Malaysia
Tel: +603 88831229, Fax: +603 88831230; htamalaysia@moh.gov.my, www.moh.gov.my

Reference Technology Review Report - 002/2011, http://www.moh.gov.my/technology_reviews/185

Aim
To assess the safety, efficacy or effectiveness and cost-effectiveness of Hybrid Cochlear Implant.

Conclusions and results
There was low level evidence retrieved on the efficacy and effectiveness of the Hybrid Cochlear Implant for the treatment of severe to profound sensorineural hearing loss. However, there are still ongoing phase I/II clinical trials of the Hybrid Cochlear Implant in the United States of America, involving the manufacturing companies, audiology and ear institutes, and also medical universities. There was limited and poor level evidence to suggest the safety of the Hybrid Cochlear Implant for the treatment of sensorineural hearing loss. There was no retrievable evidence on the cost-effectiveness of the Hybrid Cochlear Implant for the treatment of sensorineural hearing loss.

Recommendations
The use of the Hybrid Cochlear Implant in treating severe to profound high frequency sensorineural hearing loss needs further evaluation and should be recommended for research purposes.

Methods
Electronic databases were searched, which included PubMed, Ovid Medline, EBM Reviews-Cochrane Central Register of Controlled Trials, EBM Reviews-Cochrane database of systemic reviews, Horizon Scanning, US FDA website and general search engine Google for published reports. There was no limit in the search.

Further research/reviews required
More clinical research on effectiveness and safety of the Hybrid Cochlear Implant is required.

Written by
Hanin FK, MaHTAS, Malaysia